Liraglutide

Drug Profile

Liraglutide

Alternative Names: LATIN T1D; NN 2211; NN 9211; NN-8022; NNC 90-1170; Saxenda; Victoza

Latest Information Update: 24 Nov 2016

Price : $50

At a glance

  • Originator Novo Nordisk
  • Developer Hvidovre Hospital; Novo Nordisk
  • Class Antihyperglycaemics; Glucagon-like peptides; Obesity therapies
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Obesity; Type 2 diabetes mellitus
  • Discontinued Type 1 diabetes mellitus

Most Recent Events

  • 22 Nov 2016 Novo Nordisk plans the phase III trial for Obesity and Type-2 diabetes mellitus in USA, Germany and Mexico (NCT02963922)
  • 18 Nov 2016 Novo Nordisk plans a phase III trial for Obesity (Adjunctive treatment) in USA (SC) (NCT02963935)
  • 11 Nov 2016 Novo Nordisk plans the phase III LIRA-ADD2SGLT2i trial for Type-2 diabetes mellitus (Adjunctive treatment) in USA, Brazil, India, Israel, Mexico, Russia and United Arab Emirates (SC) (NCT02964247)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top